Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
09/2003
09/11/2003US20030170297 Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin
09/11/2003US20030170289 Injectable depot compositions and uses thereof
09/11/2003US20030170274 Activation of HCV-specific T cells
09/11/2003US20030170273 Type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules for enhancing the immune response of a coadministered antigen
09/11/2003US20030170265 Use of grifola frondosa fungus extracts
09/11/2003US20030170264 Stabilisation of plasmid inheritance in bacteria
09/11/2003US20030170262 Immunogenic detoxified mutant E. coli LT-A toxin
09/11/2003US20030170233 Treating Autoimmune Diseases with Humanized Anti-CD40L Antibody
09/11/2003US20030170232 Downmodulating an autoimmune response by administering an antigen binding portion of an anti-CD28 antibody that blocks signaling via CD28
09/11/2003US20030170217 Bifidobacterium in the treatment of inflammatory disease
09/11/2003US20030170212 Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
09/11/2003US20030170211 For delivering alphavirus replicon DNA into an animal or animal cells with the replicon encoding one or more heterologous genes to be expressed in the animal or the animal cells
09/10/2003EP1343013A1 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents.
09/10/2003EP1342779A1 Means and methods for manipulating hypersensitivity-like responses
09/10/2003EP1342729A2 Antibodies and antisense molecules for G-coupled receptor showing selective affinity for ATP
09/10/2003EP1342723A1 Indole derivatives and use thereof in medicines
09/10/2003EP1342469A2 Stable glass state powder formulations
09/10/2003EP1341921A2 Hydrolases
09/10/2003EP1341920A2 Human elongase genes and uses thereof
09/10/2003EP1341915A1 Use of cells derived from embryonic stem cells for increasing transplantation tolerance and for repairing damaged tissue
09/10/2003EP1341908A2 Targeted enzyme prodrug therapy
09/10/2003EP1341907A2 Target enzymes
09/10/2003EP1341819A2 Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament
09/10/2003EP1341811A2 Orally ingestible preparation of mistletoe lectins and method
09/10/2003EP1341809A2 Glycoprotein peptide of the human herpesvirus-7 for use in particular in an elisa serologic test
09/10/2003EP1341807A2 Interferon-alpha induced gene
09/10/2003EP1341792A2 Amido ether substituted imidazoquinolines
09/10/2003EP1341791A2 Thioether substituted imidazoquinolines
09/10/2003EP1341790A2 Sulfonamido ether substituted imidazoquinolines
09/10/2003EP1341789A2 Aryl ether substituted imidazoquinolines
09/10/2003EP1341782A2 Inhibitors of p38 kinase
09/10/2003EP1341767A2 Imidazole and benzimidazole caspase inhibitors and uses thereof
09/10/2003EP1341754A1 Substituted anthranilic acids
09/10/2003EP1341553A1 Silensed anti-cd28 antibodies and use thereof
09/10/2003EP1341552A2 Treatment of immune-mediated diseases by oral administration of plasma fractions
09/10/2003EP1341546A2 Kyberdrug as autovaccines with immune-regulating effects
09/10/2003EP1341537A2 Pharmaceutically active isoindoline derivatives
09/10/2003EP1312373A8 Antiallergic agents, drugs, foods, drinks or cosmetics containing them and process for producing the same
09/10/2003EP1156814B1 Pharmaceuticals, dietary supplements and cosmetic compositions comprising a fatty acid and ginger
09/10/2003EP1131080B1 Selection and uses of lactic acid bacteria strains modulating non-specific immunity
09/10/2003EP1085816B1 Dietary supplement derived from fermented milks for the prevention of osteoporosis
09/10/2003EP0973501B1 Aqueous suspension for nasal administration of loteprednol
09/10/2003EP0914091B1 Ethene containing solutions and use thereof in methods of therapy or prophylaxis
09/10/2003EP0873341B1 Epothilone derivatives, preparation and use
09/10/2003EP0772396B1 Method of regulating immune function
09/10/2003EP0594732B1 Humanized antibody against cd18
09/10/2003CN1441843A Extracellular matrix protein
09/10/2003CN1441842A Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof
09/10/2003CN1441810A Soluble CTL A4 mutant molecules and use thereof
09/10/2003CN1441808A Chemokine receptor modulators, production and use
09/10/2003CN1441803A Indoloquinazolinones
09/10/2003CN1441787A Modulators of TNF-alpha signaling
09/10/2003CN1441785A Tetrahydroixoquinoline analogs useful as growth hormone secretagogues
09/10/2003CN1441782A N-oxides as NK1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
09/10/2003CN1441781A Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
09/10/2003CN1441780A Piperidine compounds for use as CCR-3 inhibitors
09/10/2003CN1441779A Proline derivatives and use thereof as drugs
09/10/2003CN1441776A Novel aryl, alkenyl and alkynl 4-dedimethylamino tetracycline derivatives
09/10/2003CN1441770A Modified forms of pharmacologically active agents and uses therefor
09/10/2003CN1441676A Method of treatment using ligand-immunogen conjugates
09/10/2003CN1441675A Compositions and methods for achieving immune suppression
09/10/2003CN1440980A Mannosan peptide and its prepn and use
09/10/2003CN1440816A Improvement for diagnosis and/or therapeutic agnet and its relative improvement
09/09/2003US6617428 Immunoglobulin M(IgM); given amino acid sequence; immunomodulators; use in blocking or inhibiting humoral immune responses in transplant patients
09/09/2003US6617426 Peptide analogs of given formula; useful in treating neurodegenerative, autoimmune, cognitive disorders, stroke and traumatic injury
09/09/2003US6617361 Protocol for prevention of Alzheimer's disease involves stimulating implicit memory; psychotherapeutic or psychological supports; stimulating explicit memory; transfers learned behavior into the implicit memory.
09/09/2003US6617345 Cyclooxygenase-2 inhibitor is (5-bromo-2-(4-fluorophenyl )-3-(4-(methylsulfonyl)phey)-thiophene), N-(2-(cyclohexyloxy 4-nitrophenyl)-methanesulfonamide), meloxicam, flosulide or cyclic substituted phenyl sulfones or sulfonamides
09/09/2003US6617344 Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them
09/09/2003US6617317 Boronic ester and acid compositions
09/09/2003US6617171 Detecting immunological defects in mammal; obtain sample tissue from mammal, detect proteasome activity, reduction in proteasome activty indicates immunological defect
09/09/2003US6617135 Multiple cytokine protein complexes
09/09/2003CA2263566C Substituted 6,5-hetero-bicyclic derivatives
09/09/2003CA2244867C Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
09/09/2003CA2062105C Purified mite allergen
09/04/2003WO2003073351A2 Screening process
09/04/2003WO2003072789A2 Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors
09/04/2003WO2003072781A1 Mite galectin
09/04/2003WO2003072740A2 Novel type-1 cytokine receptor glm-r
09/04/2003WO2003072736A2 Reagents and treatment methods for autoimmune diseases
09/04/2003WO2003072720A2 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
09/04/2003WO2003072719A2 Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences
09/04/2003WO2003072704A2 RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
09/04/2003WO2003072604A1 Transmembrane nfat inhibitory peptide
09/04/2003WO2003072601A1 Method for producing hypoallergenic major birch pollen allergens rbet v 1
09/04/2003WO2003072569A1 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
09/04/2003WO2003072558A2 Arylsulfone derivatives
09/04/2003WO2003072557A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
09/04/2003WO2003072556A1 Glutaminyl based dpiv inhibitors
09/04/2003WO2003072550A1 Novel fused ring indazole compounds
09/04/2003WO2003072545A1 Cyclic amine compound and ccr3 inhibitory drug containing the same as active ingredient
09/04/2003WO2003072539A1 Phenethanolamine derivatives for treatment of respiratory diseases
09/04/2003WO2003072159A1 N-{5-[4-(4-methyl-piperazino-methyl)­-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
09/04/2003WO2003072135A2 Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
09/04/2003WO2003072120A1 The use of the total coumarins of cnidium monnieri in preparation of the medicament for treating psoriasis
09/04/2003WO2003072115A1 Ceramic composite materials
09/04/2003WO2003072114A1 Vascular therapeutics
09/04/2003WO2003072110A1 Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases
09/04/2003WO2003072109A1 Use of biogenic estriol sulfamate prodrugs for the treatment of autoimmune diseases
09/04/2003WO2003072107A1 Substituted pyrimidinones and pyrimidinthiones
09/04/2003WO2003072088A1 Capsule for the time-delayed dispensing of nutrients and/or active substances
1 ... 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 ... 1172